You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Practical Considerations for First-Line Management of Patients With ALK-Positive NSCLC

  • Authors: Alexander Spira, MD, PhD, FACP; D. Ross Camidge, MD, PhD
  • CME / ABIM MOC Released: 9/23/2022
  • Valid for credit through: 9/23/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, pulmonologists, pathologists, and other members of the multidisciplinary care team.

The goal of this activity is that learners will be better able to manage patients with ALK-positive metastatic NSCLC in the frontline setting.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical trial data evaluating ALK inhibitors for the management of patients with ALK-positive NSCLC
  • Have greater competence related to
    • Personalizing care for patients with ALK-positive NSCLC
    • Managing treatment-related adverse events (AEs) associated with ALK inhibitors
  • Demonstrate greater confidence in their ability to
    • Communicate treatment expectations to patients with ALK-positive NSCLC


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Alexander Spira, MD, PhD, FACP

    Medical Oncologist
    Director, VCS Research Institute
    and Phase I Trial Program
    Virginia Cancer Specialists
    Fairfax, Virginia

    Disclosures

    Alexander Spira, MD, PhD, FACP, has the following relevant financial relationships:
    Consultant or advisor for: Amgen; Array BioPharma; AstraZeneca/MedImmune; Blueprint Medicines; Bristol Myers Squibb; Daiichi Sankyo/AstraZeneca; Gritstone Bio; Gritstone Oncology; Incyte; Janssen Research & Development; Jazz Pharmaceuticals; Merck; Mersana; Mirati Therapeutics; Novartis; Regeneron; Takeda
    Research funding from: Abbvie; ADCT; Alkermes; Amgen; Arch Therapeutics; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; CytomX Therapeutics; Daiichi Sankyo; Gritstone; Ignyta; Incyte; Janssen Oncology; LAM Therapeutics; Loxo; Macrogenics; MedImmune; Mersana; Mirati Therapeutics; Newlink Genetics; Novartis; Plexxikon; Regeneron; Revolution Medicines; Roche; Rubius; Synthekine; Takeda; Trovagene
    Own Stock (publicly held): Eli Lilly
    Other – Honoraria from: Amgen; AstraZeneca/MedImmune; Bayer; Bristol Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda

  • D. Ross Camidge, MD, PhD

    Professor of Medicine/Oncology
    Joyce Zeff Chair in Lung Cancer Research
    Director of Thoracic Oncology
    University of Colorado Cancer Center
    Aurora, Colorado

    Disclosures

    D. Ross Camidge, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Appollomics; Amgen; Anchiarno; AnHeart Therapeutics; AstraZeneca/Daiichi Sankyo; BeiGene; Dizal Pharma; Bio-Thera Solutions; Blueprint Medicines; Bristol Myers Squibb; EMD Serono; Daiichi-Sankyo; Eisai; Elevation Oncology; Eli Lilly; GlaxoSmithKline; Jiangsu Hengrui; Helssin; Hummingbird; Janssen; Kestrel; Medtronic; Mersana Therapeutics; Mirati Therapeutics; Nalo Therapeutics; Nuvalent; OnKure Therapeutics; Pfizer; Puma Biotechnology; Qilu Pharmaceutical; Ribon Therapeutics; Sanofi; Seagen Inc., formerly Seattle Genetics, Inc.; Roche; Takeda Pharmaceutical; Turning Point Therapeutics
    Research funding from: AbbVie; AstraZeneca; Blueprint Medicines; Dizal Pharma; Inhibrx; Inivata; Karyopharm; Pfizer; Phosplatin Therapeutics; PsiOxus Therapeutics; Rain Therapeutics; Roche/Genentech; Seagen formerly Seattle Genetics; Takeda Pharmaceutical; Turning Point Therapeutics; Verastem Oncology

Editors

  • Amy Furedy, RN, OCN

    Medical Education Director, Medscape, LLC

    Disclosures

    Amy Furedy, RN, OCN, has disclosed no relevant financial relationships.

  • Yoji Yamaguchi, MA, ELS

    Scientific Content Manager, Medscape, LLC

    Disclosures

    Yoji Yamaguchi, MA, ELS, has disclosed no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Practical Considerations for First-Line Management of Patients With ALK-Positive NSCLC

Authors: Alexander Spira, MD, PhD, FACP; D. Ross Camidge, MD, PhDFaculty and Disclosures

CME / ABIM MOC Released: 9/23/2022

Valid for credit through: 9/23/2023

processing....

Educational Impact Challenge

The goal of this activity is that learners will be better able to manage patients with ALK-positive metastatic NSCLC in the frontline setting.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.